

CITATION REPORT

List of articles citing

Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study

DOI: 10.1097/qai.0000000000000225

Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 52-8.

Source: <https://exaly.com/paper-pdf/58482798/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
182	Reaching the unreached: treatment as prevention as a workable strategy to mitigate HIV and its consequences in high-risk groups. 2014 , 11, 505-12		12
181	The role of drug transporters in the kidney: lessons from tenofovir. 2014 , 5, 248		43
180	A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection. 2014 , 11, 35		12
179	HIV: new drugs, new guidelines. <i>Current Opinion in Infectious Diseases</i> , 2014 , 27, 545-53	5.4	16
178	Beginning antiretroviral therapy for patients with HIV. 2014 , 28, 421-38		5
177	Meta-Analysis of Studies Comparing Single and Multi-Tablet Fixed Dose Combination HIV Treatment Regimens. <i>Medicine (United States)</i> , 2015 , 94, e1677	1.8	71
176	Current state and limitations of daily oral therapy for treatment. <i>Current Opinion in HIV and AIDS</i> , 2015 , 10, 219-25	4.2	24
175	Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015 , 69, 439-45	3.1	123
174	Challenges and Clinical Decision-Making in HIV-to-HIV Transplantation: Insights From the HIV Literature. 2015 , 15, 2023-30		46
173	The role of dolutegravir in the management of HIV infection. 2015 , 8, 19-29		11
172	Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors. 2015 , 110, 847-64		17
171	Towards the elimination and eradication of hepatitis B. <i>Journal of Virus Eradication</i> , 2015 , 1, 4-12	2.8	6
170	Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 3563-9	5.9	98
169	Ageing with HIV: a multidisciplinary review. <i>Infection</i> , 2015 , 43, 509-22	5.8	19
168	The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists. 2015 , 28, 393-402		13
167	Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use. 2015 , 4, 145-57		21
166	Limited use for dual treatment with boosted protease inhibitors plus lamivudine in first-line antiretroviral therapy. 2015 , 15, 748-9		

165	HIV integrase inhibitors: a new era in the treatment of HIV. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 1313-24	4	42
164	Tenofovir alafenamide: an effective option for HIV treatment with reduced risk. <i>Future Virology</i> , 2015 , 10, 1069-1075	2.4	
163	Do we need more nucleos(t)ide analogs for the treatment of chronic hepatitis B?. 2015 , 62, 505-7		2
162	Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. 2015 , 62, 533-40		124
161	Characterization of HIV-1 Resistance to Tenofovir Alafenamide In Vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 5917-24	5.9	33
160	In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to That of Tenofovir Disoproxil Fumarate. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 5909-16	5.9	59
159	Future challenges for clinical care of an ageing population infected with HIV: a modelling study. 2015 , 15, 810-8		438
158	Bone Disease in HIV: Recommendations for Screening and Management in the Older Patient. 2015 , 32, 549-58		5
157	Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. 2015 , 385, 2606-15		433
156	Editorial Commentary: Unmasking the Bare Bones of HIV Preexposure Prophylaxis. <i>Clinical Infectious Diseases</i> , 2015 , 61, 581-3	11.6	2
155	Commentary: The place of tenofovir disoproxil fumarate in pediatric antiretroviral therapy. 2015 , 34, 406-8		3
154	New paradigms in hepatitis B management: only diamonds are forever. 2015 , 116, 79-91		8
153	Antiviral Drugs. 2015 , 37, 329-348		
152	Hepatitis B: Working Towards a Cure. 2015 , 17, 35		
151	ARVs: the next generation. Going boldly together to new frontiers of HIV treatment. 2015 , 3, 1-11		31
150	Ensuring new medicines reach those in most need. 2015 , 2, e362-3		2
149	Antiretroviral Agent. 2016 , 169-214		0
148	Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection. 2016 , 8, 47-65		3

147	Is Abnormal Urine Protein/Osmolality Ratio Associated with Abnormal Renal Function in Patients Receiving Tenofovir Disoproxil Fumarate?. <i>PLoS ONE</i> , 2016 , 11, e0149562	3.7	
146	Projected Uptake of New Antiretroviral (ARV) Medicines in Adults in Low- and Middle-Income Countries: A Forecast Analysis 2015-2025. <i>PLoS ONE</i> , 2016 , 11, e0164619	3.7	25
145	Real-World Assessment of Renal and Bone Safety among Patients with HIV Infection Exposed to Tenofovir Disoproxil Fumarate-Containing Single-Tablet Regimens. <i>PLoS ONE</i> , 2016 , 11, e0166982	3.7	8
144	Choice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?. 2016 , 19, 20504		23
143	Tenofovir and bone health. <i>Current Opinion in HIV and AIDS</i> , 2016 , 11, 326-32	4.2	73
142	The role of tenofovir alafenamide in future HIV management. <i>HIV Medicine</i> , 2016 , 17 Suppl 2, 4-16	2.7	32
141	Higher tenofovir exposure is associated with longitudinal declines in kidney function in women living with HIV. <i>Aids</i> , 2016 , 30, 609-18	3.5	27
140	Preventing long-term tenofovir renal toxicity by pharmacokinetic assessment. <i>Aids</i> , 2016 , 30, 665-6	3.5	2
139	Impact of tenofovir disoproxil fumarate on bone metabolism and bone mass among perinatally HIV-infected Asian adolescents. <i>Antiviral Therapy</i> , 2017 , 22, 471-479	1.6	6
138	The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis. <i>Medicine (United States)</i> , 2016 , 95, e5146	1.8	56
137	Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection. 2016 , 76, 957-68		17
136	Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 5135-40	5.9	48
135	High resistance barrier to tenofovir alafenamide is driven by higher loading of tenofovir diphosphate into target cells compared to tenofovir disoproxil fumarate. <i>Antiviral Research</i> , 2016 , 132, 50-8	10.8	23
134	Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). 2016 , 119, 1-7		92
133	British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. <i>HIV Medicine</i> , 2016 , 17 Suppl 4, s2-s104	2.7	63
132	Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy. 2016 , 13, 297-308		15
131	Tenofovir Alafenamide. 2016 , 50, 942-952		36
130	New Antiretroviral Treatment for HIV. 2016 , 5, 329-52		13

129	Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection. 2016 , 17, 246-266		22
128	Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients. 2016 , 14, 1113-1126		6
127	HIV and ageing: improving quantity and quality of life. <i>Current Opinion in HIV and AIDS</i> , 2016 , 11, 527-536	4.2	80
126	Brief Report: Cumulative Tenofovir Disoproxil Fumarate Exposure is Associated With Biomarkers of Tubular Injury and Fibrosis in HIV-Infected Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016 , 73, 177-81	3.1	10
125	Tenofovir exposure alters associations of serum bicarbonate with chronic kidney disease risk in HIV-infected veterans. <i>Aids</i> , 2016 , 30, 1049-57	3.5	
124	The current treatment situation and definitions of a cure for chronic HBV infection. <i>Future Virology</i> , 2016 , 11, 79-92	2.4	2
123	Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide. 2016 , 17, 78-87		12
122	Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. 2016 , 3, e158-65		118
121	Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial. 2016 , 3, e13-22		8
120	Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. 2016 , 3, e23-32		129
119	An Improved Process for the Preparation of Tenofovir Disoproxil Fumarate. 2016 , 20, 742-750		8
118	Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. <i>Antiviral Research</i> , 2016 , 125, 63-70	10.8	235
117	Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 409-19	4	8
116	Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 316-22	5.9	50
115	Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV. 2017 , 15, 195-209		14
114	Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures. <i>Antiviral Research</i> , 2017 , 140, 116-120	10.8	13
113	Emtricitabine + tenofovir alafenamide for the treatment of HIV. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 427-432	4	9
112	Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. 2017 , 4, e205-e213		33

111	Impact of tenofovir dose adjustment on both estimated glomerular filtration rate and tenofovir trough concentration. <i>Antiviral Therapy</i> , 2017 , 22, 529-533	1.6	3
110	Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate. <i>Antiviral Therapy</i> , 2017 , 22, 443-446	1.6	7
109	Atazanavir sulfate + cobicistat for the treatment of HIV infection. 2017 , 15, 569-576		6
108	Single-Tablet Regimens for the Treatment of HIV-1 Infection. 2017 , 51, 332-344		17
107	Tenofovir alafenamide demonstrates broad cross-genotype activity against wild-type HBV clinical isolates and maintains susceptibility to drug-resistant HBV isolates in vitro. <i>Antiviral Research</i> , 2017 , 139, 25-31	10.8	24
106	The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development. <i>Aids</i> , 2017 , 31 Suppl 2, S173-S184	3.5	18
105	Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model. 2017 , 34, 2749-2755		24
104	Diagnostic challenges of kidney diseases in HIV-infected patients. 2017 , 15, 903-915		8
103	Simultaneous determination of tenofovir alafenamide and its active metabolites tenofovir and tenofovir diphosphate in HBV-infected hepatocyte with a sensitive LC-MS/MS method. 2017 , 146, 147-153		10
102	Kidney Disease in HIV: Moving beyond HIV-Associated Nephropathy. 2017 , 28, 3142-3154		21
101	Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study. 2017 , 20, 21678		54
100	Nonhuman Primate Models for Studies of AIDS Virus Persistence During Suppressive Combination Antiretroviral Therapy. 2018 , 417, 69-109		11
99	New Antiretrovirals for HIV and Antivirals for HBV. 2017 , 628-664		
98	Patterns of vitamin D, parathyroid hormone and c-terminal telopeptide of collagen type 1 in Caucasian and African descent HIV-infected populations in Central Europe. 2017 , 9, 7265		3
97	Current and future directions of management of hepatitis B: steps toward a cure. <i>Future Virology</i> , 2018 , 13, 189-209	2.4	1
96	Adipocytes impair efficacy of antiretroviral therapy. <i>Antiviral Research</i> , 2018 , 154, 140-148	10.8	25
95	Recent progress in potential anti-hepatitis B virus agents: Structural and pharmacological perspectives. <i>European Journal of Medicinal Chemistry</i> , 2018 , 147, 205-217	6.8	14
94	Treatment of HCV, HDV, or HIV Coinfection. 2018 , 239-262		2

93	Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. <i>Aids</i> , 2018 , 32, 761-765	3.5	39
92	Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial. <i>Clinical Infectious Diseases</i> , 2018 , 66, 220-228	11.6	30
91	Next generation fixed dose combination pharmacotherapies for treating HIV. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 589-596	4	14
90	Anti-retroviral drugs: current state and development in the next decade. <i>Acta Pharmaceutica Sinica B</i> , 2018 , 8, 131-136	15.5	24
89	A Review of the Efficacy and Safety of Genvoya [®] (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection. 2018 , 31, 216-221		17
88	Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections. 2018 , 153, 2-11		27
87	Canadian guidelines on HIV pre-exposure prophylaxis (PrEP) and non-occupational post-exposure prophylaxis (nPEP): Discussion beyond the guidelines and commentary on the role of infectious diseases specialists. 2018 , 3, 165-177		2
86	Feasibility of vitamin D supplementation interventions to mitigate HIV pre-exposure prophylaxis-related bone mineral density loss: a cross-sectional survey. 2018 , 12, 2197-2204		2
85	Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?. <i>Journal of Virus Eradication</i> , 2018 , 4, 72-79	2.8	62
84	Fanconi syndrome due to tenofovir disoproxil fumarate reversed by switching to tenofovir alafenamide fumarate in an HIV-infected patient. 2018 , 5, 91-95		9
83	Measurement of plasma HIV-1 RNA below the limit of quantification (. 2018 , 108, 50-52		8
82	The Hidden Burden of Fractures in People Living With HIV. <i>JBMR Plus</i> , 2018 , 2, 247-256	3.9	22
81	Dual antiretroviral therapy with tenofovir (TDF) and darunavir/ritonavir (DRV/RTV) in an HIV-1 positive patient: a case report, review, and meta-analysis of the literature on dual treatment strategies using protease inhibitors in combination with an NRTI. <i>Infection</i> , 2018 , 46, 599-605	5.8	1
80	Drug Interactions in HIV: Nucleoside, Nucleotide, and Nonnucleoside Reverse Transcriptase Inhibitors and Entry Inhibitors. 2018 , 297-356		1
79	A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicity. <i>Aids</i> , 2018 , 32, 1633-1641	3.5	8
78	Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 2112-2119	5.1	11
77	Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis. <i>Journal of Controlled Release</i> , 2018 , 286, 315-325	11.7	48
76	Tenofovir alafenamide fumarate attenuates bleomycin-induced pulmonary fibrosis by upregulating the NS5ATP9 and TGF- β /Smad3 signaling pathway. <i>Respiratory Research</i> , 2019 , 20, 163	7.3	2

75	Alopecia After Switch to Tenofovir Alafenamide in 6 African American Women. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz278	1	3
74	The Changing Face of Human Immunodeficiency Virus-Mediated Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2019 , 26, 185-197	4.7	7
73	Changes in Body Mass Index and Atherosclerotic Disease Risk Score After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz414	1	39
72	Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. <i>Aids</i> , 2019 , 33, 1455-1465	3.5	60
71	Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 385-397	4.3	8
70	HIV infection and coronary heart disease: mechanisms and management. <i>Nature Reviews Cardiology</i> , 2019 , 16, 745-759	14.8	44
69	Planning HIV therapy to prevent future comorbidities: patient years for tenofovir alafenamide. <i>HIV Medicine</i> , 2019 , 20 Suppl 7, 1-16	2.7	8
68	Renal dysfunction by baseline CD4 cell count in a cohort of adults starting antiretroviral treatment regardless of CD4 count in the HIV Prevention Trials Network 071 [HPTN 071; Population Effect of Antiretroviral Therapy to Reduce HIV Transmission (PopART)] study in South Africa. <i>HIV Medicine</i> , 2019 , 20, 392-403	2.7	1
67	Coronary Artery Disease. 2019 , 129-139		
66	Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 1670-1678	5.1	22
65	Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019 , 82, 252-256	3.1	7
64	Update on HIV integrase inhibitors for the treatment of HIV-1 infection. <i>Future Virology</i> , 2019 , 14, 693-704	4.1	2
63	Switching tenofovir disoproxil fumarate to tenofovir alafenamide results in a significant decline in parathyroid hormone levels: uncovering the mechanism of tenofovir disoproxil fumarate-related bone loss?. <i>Aids</i> , 2019 , 33, 1531-1534	3.5	5
62	In vitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2. <i>Antiviral Research</i> , 2019 , 161, 85-89	10.8	2
61	Lipid Abnormalities in Persons Living With HIV Infection. <i>Canadian Journal of Cardiology</i> , 2019 , 35, 249-258	3.8	17
60	Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability. <i>Clinical Pharmacology in Drug Development</i> , 2019 , 8, 480-491	2.3	2
59	Two drugs regimens for HIV. <i>Current Opinion in Infectious Diseases</i> , 2020 , 33, 28-33	5.4	2
58	Tenofovir alafenamide does not inhibit mitochondrial function and cholesterol biosynthesis in human T lymphoblastoid cell line. <i>Antiviral Research</i> , 2020 , 183, 104948	10.8	1

57	Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials. <i>Aids</i> , 2020 , 34, 2259-2268	3.5	13
56	Tenofovir alafenamide and rifabutin co-administration does not lead to loss of HIV-1 suppression: A retrospective observational study. <i>International Journal of Infectious Diseases</i> , 2020 , 100, 470-472	10.5	
55	Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3303-3310	5.1	2
54	Tenofovir Alafenamide Fumarate Therapy for HIV Treatment: Cardiometabolic and Renal Safety. <i>AIDS Research and Human Retroviruses</i> , 2020 , 36, 697-702	1.6	
53	Nephrotoxicity of Antimicrobials and Antibiotics. <i>Advances in Chronic Kidney Disease</i> , 2020 , 27, 31-37	4.7	38
52	People living with HIV and fracture risk. <i>Osteoporosis International</i> , 2020 , 31, 1633-1644	5.3	12
51	Switching tenofovir disoproxil fumarate to tenofovir alafenamide in a real life setting: what are the implications?. <i>HIV Medicine</i> , 2020 , 21, 378-385	2.7	11
50	Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials. <i>International Journal of Infectious Diseases</i> , 2020 , 93, 108-117	10.5	21
49	Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	5
48	A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide. <i>Journal of the International Association of Providers of AIDS Care</i> , 2020 , 19, 2325958220919231	1.7	21
47	Dyslipidaemia after switch to tenofovir alafenamide (TAF)-based cART regimens in a cohort of HIV-positive patients: what clinical relevance?. <i>HIV Medicine</i> , 2021 , 22, 140-145	2.7	4
46	Sequential therapy from entecavir to tenofovir alafenamide continuous entecavir monotherapy for patients with chronic hepatitis B. <i>JGH Open</i> , 2021 , 5, 34-40	1.8	3
45	Longitudinal change in bone mineral density among Chinese individuals with HIV after initiation of antiretroviral therapy. <i>Osteoporosis International</i> , 2021 , 32, 321-332	5.3	7
44	Treatment of HCV, HDV, or HIV Coinfections. 2021 , 339-373		
43	Real-Life Impact on Lipid Profile of a Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected Patients. <i>Current HIV Research</i> , 2021 , 19, 84-89	1.3	3
42	Drug Discovery of Nucleos(t)ide Antiviral Agents: Dedicated to Prof. Dr. Erik De Clercq on Occasion of His 80th Birthday. <i>Molecules</i> , 2021 , 26,	4.8	10
41	Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART. <i>Drug Testing and Analysis</i> , 2021 , 13, 1354-1370	3.5	1
40	Antiretroviral drug exposure in urethral and glans surface sampling of the penis. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 2368-2374	5.1	0

39	Evaluation of kidney function tests in HIV-positive patients receiving combined antiretroviral therapy. <i>International Journal of Clinical Practice</i> , 2021 , 75, e14542	2.9	0
38	Development, Characterization and In Vivo Pharmacokinetic Assessment of Rectal Suppositories Containing Combination Antiretroviral Drugs for HIV Prevention. <i>Pharmaceutics</i> , 2021 , 13,	6.4	0
37	Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide. <i>Drugs in Context</i> , 2021 , 10,	5.2	1
36	Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen. <i>Medicine (United States)</i> , 2021 , 100, e27047	1.8	0
35	Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate. <i>Aids</i> , 2021 , 35, 2481-2487	3.5	0
34	An unexpected adverse effect: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide-induced cholestasis.. <i>Antiviral Therapy</i> , 2021 , 26, 9-12	1.6	1
33	Avoiding Drug Resistance in HIV Reverse Transcriptase. <i>Chemical Reviews</i> , 2021 , 121, 3271-3296	68.1	18
32	Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide. <i>Current Opinion in HIV and AIDS</i> , 2017 , 12, 324-333	4.2	21
31	Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations. <i>PLoS ONE</i> , 2017 , 12, e0169948	3.7	4
30	Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome. <i>PLoS ONE</i> , 2017 , 12, e0172206	3.7	18
29	Integrase Inhibitor-Based Antiretroviral Therapy Among Women Living with HIV: Data from the OPERA Cohort. <i>Current HIV Research</i> , 2019 , 17, 266-276	1.3	1
28	Search for a cure for chronic hepatitis B infection: How close are we?. <i>World Journal of Hepatology</i> , 2015 , 7, 1272-81	3.4	12
27	Towards the worldwide eradication of hepatitis B virus infection: A combination of prophylactic and therapeutic factors. <i>World Journal of Clinical Infectious Diseases</i> , 2019 , 9, 11-22	0.7	4
26	HIV pre-exposure prophylaxis and sexually transmitted infections: intersection and opportunity. <i>Nature Reviews Urology</i> , 2021 ,	5.5	0
25	Acute HIV Infection in Youth: Protocol for the Adolescent Trials Network 147 (ATN147) Comprehensive Adolescent Research and Engagement Studies (CARES) Study (Preprint).		
24	Acute HIV Infection in Youth: Protocol for the Adolescent Trials Network 147 (ATN147) Comprehensive Adolescent Research and Engagement Studies (CARES) Study. <i>JMIR Research Protocols</i> , 2019 , 8, e10807	2	5
23	Prescribing rates and characteristics of recipients of tenofovir-containing regimens before and after market entry of tenofovir alafenamide. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020 , 26, 1582-1588	1.9	0
22	HIV Infection, HIV Therapy, and Bone Health. 2020 , 146-155		

21	Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B. <i>Intervirology</i> , 2021 , 1-10	2.5	1
20	Clinical pharmacist input on HIV management may improve antiretroviral prescribing for psychiatric patients. <i>American Journal of Health-System Pharmacy</i> , 2021 , 78, S10-S15	2.2	1
19	Towards the elimination and eradication of hepatitis B. <i>Journal of Virus Eradication</i> , 2015 , 1, 4-12	2.8	2
18	Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?. <i>Journal of Virus Eradication</i> , 2018 , 4, 72-79	2.8	36
17	Treatment Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents: An Update. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2016 , 33, 31S-36S	2.7	5
16	Approved HIV reverse transcriptase inhibitors in the past decade. <i>Acta Pharmaceutica Sinica B</i> , 2021 , ,	15.5	6
15	Tenofovir alafenamide plasma concentrations are reduced in pregnant women living with HIV: data from the PANNA Network. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	0
14	Human immunodeficiency virus and acquired immunodeficiency syndrome: recent developments and their implications for pediatric surgeons. <i>Seminars in Pediatric Surgery</i> , 1995 , 4, 252-61	2.1	
13	Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: a propensity score-matched analysis.. <i>Clinical and Molecular Hepatology</i> , 2021 ,	6.9	0
12	Tenofovir alafenamide (TAF) clinical pharmacology.. <i>Infezioni in Medicina</i> , 2021 , 29, 526-529	3.6	
11	Optimizing the antiretroviral treatment focusing on long-term effectiveness and a person-centred approach. Consensus Guidance Using a Delphi Process.		
10	Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue. <i>Pharmaceutics</i> , 2022 , 14, 1285	6.4	
9	HIV nucleoside reverse transcriptase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2022 , 114554	6.8	1
8	Weight changes in patients with sustained viral suppression switching tenofovir disoproxil fumarate to tenofovir alafenamide. <i>Obesity</i> , 2022 , 30, 1197-1204	8	
7	Clinical Considerations in the Selection of Preexposure Prophylaxis for HIV Prevention in Canada. 2022 , 2022, 1-14		0
6	Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models. 13,		0
5	A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection. 2022 , 19,		2
4	Renal Dysfunction Due to Tenofovir-Diphosphate Inhibition of Mitochondrial Complex V (ATP Synthase).		0

- 3 Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds. **2023**, 24, 5905
- 2 Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans. Publish Ahead of Print,
- 1 Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV. **2023**, 33, 79-87